
Corbus Pharmaceuticals Holdings, Inc.: updates and filings
Price
$2.06
November 20, 2026Market cap $42M
What Ploutos Investor adds for Corbus Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 11 fiscal years, from 2015
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 48% since Nov 10, 2026, when the 10-Q these figures come from was filed ($3.93 then, $2.06 on Nov 20, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 10, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
May 2026
- 26TueOtherRegulation FD disclosure, other material eventsDocument
- 21ThuDealMaterial agreement entered, officer or director change, Regulation FD disclosureDocument
- 14ThuPeopleOfficer or director change, shareholder vote, Regulation FD disclosureDocument
- 12TueReportQuarterly report · for the period to Mar 31, 2026Document
- 12TueResultsResults of operations, Regulation FD disclosureDocument
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Regulation FD disclosure, other material eventsForm8-K
- Nov 13, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operations, Regulation FD disclosureForm8-K
- Nov 2, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 29, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 15, 2026Regulation FD disclosureForm8-K
- Sep 30, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Sep 14, 2026Regulation FD disclosure, other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 6, 2026Material agreement entered, Regulation FD disclosureForm8-K
- Jun 17, 2026Shares registered for employeesFormS-8
- May 29, 2026Shares registered for employeesFormS-8
- May 26, 2026Regulation FD disclosure, other material eventsForm8-K
- May 21, 2026Material agreement entered, officer or director change, Regulation FD disclosureForm8-K
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Officer or director change, shareholder vote, Regulation FD disclosureForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operations, Regulation FD disclosureForm8-K
- Apr 16, 2026Additional annual meeting materialFormDEFA14A
- Apr 16, 2026Officer or director changeForm8-K
- Apr 14, 2026Regulation FD disclosure, other material eventsForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 13, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Nov 2, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 29, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 15, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 30, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Sep 14, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 6, 2026 | 8-K | Material agreement entered, Regulation FD disclosure | Document |
| Jun 17, 2026 | S-8 | Shares registered for employees | Document |
| May 29, 2026 | S-8 | Shares registered for employees | Document |
| May 26, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| May 21, 2026 | 8-K | Material agreement entered, officer or director change, Regulation FD disclosure | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | 8-K | Officer or director change, shareholder vote, Regulation FD disclosure | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Apr 16, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 16, 2026 | 8-K | Officer or director change | Document |
| Apr 14, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 10, 2014.
The full analysis
What do Corbus Pharmaceuticals's filings show?
The filings are where every one of Corbus Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.